1. Home
  2. GDL vs NTRB Comparison

GDL vs NTRB Comparison

Compare GDL & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GDL Fund The of Beneficial Interest

GDL

GDL Fund The of Beneficial Interest

SELL

Current Price

$8.28

Market Cap

90.1M

Sector

Finance

ML Signal

SELL

Logo Nutriband Inc.

NTRB

Nutriband Inc.

HOLD

Current Price

$6.28

Market Cap

72.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDL
NTRB
Founded
2006
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.1M
72.6M
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
GDL
NTRB
Price
$8.28
$6.28
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
16.6K
★ 56.2K
Earning Date
01-01-0001
12-10-2026
Dividend Yield
★ 6.02%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,036,651.00
Revenue This Year
N/A
$4,584.65
Revenue Next Year
N/A
$89.09
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$8.01
$2.80
52 Week High
$8.67
$9.19

Technical Indicators

Market Signals
Indicator
GDL
NTRB
Relative Strength Index (RSI) 43.81 46.00
Support Level $8.25 $5.68
Resistance Level $8.50 $9.19
Average True Range (ATR) 0.06 0.57
MACD -0.00 -0.14
Stochastic Oscillator 38.10 22.07

Price Performance

Historical Comparison
GDL
NTRB

About GDL GDL Fund The of Beneficial Interest

GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Share on Social Networks: